Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
| العنوان: | Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials |
|---|---|
| المؤلفون: | Yukinori Kurokawa, Yurina Saito, Rie Nakatsuka, Yoichi Makari, Masashi Hirota, Shinichi Adachi, Ryohei Kawabata, Masaaki Motoori, Kentaro Kishi, Atsushi Takeno, Makoto Yamasaki, Hiroshi Imamura, Hidetoshi Eguchi, Yuichiro Doki, Tsuyoshi Takahashi, Hiromichi Miyagaki |
| المصدر: | Annals of Gastroenterological Surgery, Vol 5, Iss 6, Pp 754-766 (2021) Annals of Gastroenterological Surgery |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, RD1-811, medicine.medical_treatment, Osteoporosis, RC799-869, Gastroenterology, Bone remodeling, law.invention, bone metabolism disorders, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, minodronate, Adverse effect, intervention, Bone mineral, business.industry, Cancer, Original Articles, active vitamin D, Diseases of the digestive system. Gastroenterology, medicine.disease, gastrectomy, Original Article, Gastrectomy, Surgery, business |
| الوصف: | Aim Osteoporosis in patients after gastrectomy is increasing with the aging of gastric cancer patients. Bisphosphonates are effective treatments for osteoporosis; however, their safety or efficacy in postgastrectomy patients has not been established. The purpose of this multicenter prospective intervention study was to investigate the impact of monthly minodronate on osteoporosis after gastrectomy. Methods Of the 261 enrolled gastric cancer patients, 164 patients were diagnosed with osteoporosis based on criteria of the Japan Society of Osteoporosis. They were randomly assigned 1:1 to groups treated with active vitamin D (VD group) or monthly minodronate (MIN group). The primary endpoint was changes in lumbar bone mineral density (L‐BMD) 12 mo after the start of administration. The secondary endpoints were changes in bone metabolism markers, adverse events (AEs), or treatment completion rates. Results There was no significant difference in patient background between the VD (n = 82) and MIN (n = 82) groups. In the MIN group, the increase in L‐BMD was significantly higher than that in the VD group (4.52% vs 1.72%, P = .001), with a significant reduction in bone metabolism markers; blood NTX (−25.6% vs −1.6%, P Monthly minodronate is safe and effective for osteoporosis after gastrectomy. |
| اللغة: | English |
| تدمد: | 2475-0328 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e256b090ec3a0e9d59f545044bb3b5 https://doaj.org/article/fdc8438e408f4faa94c5d217e0fd8a3e |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....42e256b090ec3a0e9d59f545044bb3b5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 24750328 |
|---|